Tvardi Therapeutics (NASDAQ: TVRD) posts updated investor corporate presentation

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. filed a current report to let investors know that it has released an updated corporate presentation. The new presentation, dated January 16, 2026, has been posted on the company’s website and is also included with the report as Exhibit 99.1.

The disclosure is made under Regulation FD, which is designed to ensure that all investors have access to the same information at the same time. The company also notes that this material is being furnished rather than filed, meaning it is not subject to certain liability provisions of the federal securities laws and is not automatically incorporated into other SEC filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001346830 0001346830 2026-01-16 2026-01-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 16, 2026

TVARDI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36279		75-3175693
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
3 Sugar Creek Ctr. Blvd. Suite 525 Sugar Land, Texas				77478
(Address of principal executive offices)				(Zip Code)

Registrant's telephone number, including area code: (713) 489-8654

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TVRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

On January 16, 2026, Tvardi Therapeutics, Inc. (the “Company”) made available an updated corporate presentation, which can be found on the Company’s website (the “Corporate Presentation”). The Corporate Presentation is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information contained herein and the accompanying Exhibit 99.1 is being furnished under “Item 7.01 Regulation FD Disclosure” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation, dated January 16, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TVARDI THERAPEUTICS, INC.
Date: January 16, 2026	By:	/s/ Imran Alibhai
	Name:	Imran Alibhai
	Title:	Chief Executive Officer

FAQ

What did Tvardi Therapeutics (TVRD) disclose in this 8-K filing?

Tvardi Therapeutics, Inc. disclosed that it has made an updated corporate presentation available on its website and furnished it as Exhibit 99.1 to this report.

Where can investors find Tvardi Therapeutics’ updated corporate presentation?

The updated corporate presentation is available on Tvardi Therapeutics’ website and is also included with the filing as Exhibit 99.1.

What is the date of Tvardi Therapeutics’ updated corporate presentation?

The corporate presentation furnished by Tvardi Therapeutics is dated January 16, 2026.

Under which item of Form 8-K did Tvardi Therapeutics provide this information?

Tvardi Therapeutics furnished the updated corporate presentation under Item 7.01, Regulation FD Disclosure.

Is Tvardi Therapeutics’ updated presentation considered filed for securities law purposes?

No. The company states that the information in the report and Exhibit 99.1 is furnished, not filed, and is not subject to certain liability provisions or automatically incorporated into other SEC filings.

What exhibits are included with this Tvardi Therapeutics (TVRD) 8-K?

The filing includes Exhibit 99.1, the corporate presentation dated January 16, 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.